What question did this study set out to answer?

To evaluate the effectiveness of [177Lu]Lu-PSMA-617 and [225Ac]Ac-PSMA-617 in treating castration-resistant prostate adenocarcinoma using patient-derived xenografts.

April 5, 2026Cancer Research

Preclinical Evaluation of PSMA-Targeted Radiopharmaceuticals in Prostate Cancer Models

View Full Paper

Ask AI

Bookmark

To evaluate the effectiveness of [177Lu]Lu-PSMA-617 and [225Ac]Ac-PSMA-617 in treating castration-resistant prostate adenocarcinoma using patient-derived xenografts.
Radiolabeled PSMA-617 with lutetium-177 and actinium-225 for high purity.
Conducted biodistribution studies in PSMA-positive and PSMA-negative PDX tumors.
Assessed therapeutic efficacy by measuring tumor size and body weight in treated mice.
Radiotracers achieved over 98% radiochemical purity.
Demonstrated selective uptake in PSMA-positive tumors with minimal accumulation in PSMA-negative tumors.
Significantly inhibited tumor growth in PSMA-positive PDX tumors with no serious side effects.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical evaluation demonstrates effective tumor growth inhibition in models of castration-resistant prostate adenocarcinoma, highlighting translational utility.

Cite This Study

Beckford-Vera et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcd4a79560c99a0a27f4 https://doi.org/10.1158/1538-7445.am2026-5812

View Full Paper

Ask AI

Bookmark

Implication

Preclinical evaluation demonstrates effective tumor growth inhibition in models of castration-resistant prostate adenocarcinoma, highlighting translational utility.

Preclinical Evaluation of PSMA-Targeted Radiopharmaceuticals in Prostate Cancer Models

Key Points

Discussion

Implication

Cite This Study

Preclinical Evaluation of PSMA-Targeted Radiopharmaceuticals in Prostate Cancer Models

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider